

CSD/BSE&NSE/BM/2025-26

March 30, 2026

To
The Manager
Department of Corporate Services
BSE Limited
25th Floor, P. J. Towers,
Dalal Street, Mumbai - 400 001
Scrip Code: 543064

To
The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra (E), Mumbai – 400 051
Scrip Symbol: COHANCE

Dear Sir/Madam,

Sub: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”) for appointment of Company Secretary, Compliance Officer and Key Managerial Personnel of the Company

Pursuant to Regulation 30 and other applicable provisions of the Listing Regulations, we hereby inform that based on the recommendation of the Nomination and Remuneration Committee, the Board of Directors of the Company has, at its meeting held today i.e., Monday, March 30, 2026, *inter alia*, approved the appointment of Mr. Sisir K. Mishra (Membership No. F8555) as Company Secretary, Compliance Officer and Key Managerial Personnel of the Company w.e.f. from April 9, 2026.

The details required to be disclosed under the SEBI Listing Regulations read with SEBI Circular no. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, on the captioned subject is annexed herewith.

This is for your information and record.

Thanking you.
Yours faithfully,
For **Cohance Lifesciences Limited**
(Formerly, Suven Pharmaceuticals Limited)

Himanshu Agarwal
Whole-time Director and Chief Financial Officer
(DIN: 06672915)
Encl: as above

Cohance Lifesciences Limited
(Formerly, Suven Pharmaceuticals Limited)

Corporate Office: 202, A-Wing, Galaxy Towers, Plot No.1, Hyderabad Knowledge City, TSIC, Raidurg, Hyderabad - 500081, Telangana.
Tel: +91 40 2354 9414 / 3311

Regd. Office: 215 Atrium, C-Wing, 8th Floor, 819-821, Andheri Kurla Road, Chakala MIDC, Andheri East, Mumbai, Maharashtra - 400093.
Tel: 022 6513999

CIN: L24299MH2018PLC422236 | Website: www.cohance.com | Company Email: reachus@cohance.com



Disclosure of information pursuant to Regulation 30 of the SEBI Listing Regulations read with SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024

	Name of Person	Mr. Sisir K. Mishra
1	Reason for change viz. appointment, re-appointment, resignation, removal, death or otherwise	Appointment of Mr. Sisir K. Mishra as ‘Company Secretary, Compliance Officer and Key Managerial Personnel
2	Date of appointment / re-appointment / cessation (as applicable) and term of appointment / re-appointment	Mr. Sisir K. Mishra would take over as Company Secretary, Compliance Officer and Key Managerial Personnel of the Company effective from April 9, 2026. Term: Not applicable
3	Brief profile (in case of appointment)	<p>Mr. Sisir K. Mishra is a Fellow Member of the Institute of Company Secretaries of India and holds an LL.M. from Osmania University. He has over two decades of experience in corporate secretarial, legal, governance, CSR and ESG functions across diversified sectors including infrastructure, manufacturing, IT and power.</p> <p>Mr. Mishra has handled board governance, regulatory interface, mergers, fundraising, IPO readiness, and compliance management systems. Prior to this appointment, he served as Company Secretary with NCC Limited, Paradeep Phosphates Limited, Deccan Cements Limited and KSK Group, among others.</p>
4	Disclosure of relationship between directors (in case of appointment of a director)	Not applicable

Cohance Lifesciences Limited
(Formerly, Suven Pharmaceuticals Limited)

Corporate Office: 202, A-Wing, Galaxy Towers, Plot No.1, Hyderabad Knowledge City, TSIC, Raidurg, Hyderabad - 500081, Telangana.
Tel: +91 40 2354 9414 / 3311

Regd. Office: 215 Atrium, C-Wing, 8th Floor, 819-821, Andheri Kurla Road, Chakala MIDC, Andheri East, Mumbai, Maharashtra - 400093.
Tel: 022 6513999

CIN: L24299MH2018PLC422236 | Website: www.cohance.com | Company Email: reachus@cohance.com

